Dr. Wagner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1240 Lee St
Charlottesville, VA 22908Phone+1 434-924-9333Fax+1 434-244-7526
Summary
- Dr. John Wagner is an oncologist in Charlottesville VA and is affiliated with Thomas Jefferson University Hospitals. He received his medical degree from Temple University School of Medicine and has been in practice 28 years. He specializes in cellular therapy and hematopoietic stem cell transplantation and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and CAR-T therapy.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 1992 - 1995
- University of MarylandResidency, Internal Medicine, 1989 - 1992
- Lewis Katz School of Medicine at Temple UniversityClass of 1989
Certifications & Licensure
- VA State Medical License 2022 - 2026
- WV State Medical License 2023 - 2025
- PA State Medical License 1999 - 2024
- DE State Medical License 2017 - 2023
- NJ State Medical License 2017 - 2023
- MD State Medical License 1990 - 1993
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2020-2022
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
Clinical Trials
- Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Start of enrollment: 2005 Nov 01
- Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias Start of enrollment: 2006 Jan 01
- Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact...Chetan Jeurkar, Benjamin Leiby, Shaik Rashid, Usama Gergis, Dolores Grossso
European Journal of Haematology. 2024-09-01 - Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19.Dolores Grosso, John L Wagner, Allyson O'Connor, Kaitlyn Keck, Yanping Huang
Blood Advances. 2024-08-13 - Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.Hemant S Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare
Blood Advances. 2023-11-28
Grant Support
- Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1999–2001
- Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1997–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: